Everything below concerns immune modulation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-20. Numbers and descriptions here follow the published literature rather than marketing material.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
| Property | Value | Notes |
|---|---|---|
| Primary structure | 28 amino acid residues | N-terminally acetylated |
| Net charge at neutral pH | Negative | Acidic peptide |
| Typical purity assay | Reverse-phase HPLC | UV detection near 214 nm |
| Identity confirmation | Mass spectrometry | Matches expected molecular mass |
| Reconstitution solvent | Sterile water or saline | Follow supplier instructions |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
Practical handling focuses on limiting adsorption and contamination. The peptide dissolves readily in water, and dilute solutions tend to adhere to plastic and glass surfaces, so an inert carrier protein or a defined buffer can reduce losses in laboratory work. Workers also record the counter-ion form, since an acetate or trifluoroacetate salt changes the mass balance of the weighed powder. Documentation of lot number, purity value, and storage history supports reproducibility when results from different laboratories are compared.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
== Pharmacology == The half-life varies in around 8 hours at normal doses. Excretion is 65% through urine, mostly in unmetabolized form, and 28% via feces. Clearance is reduced in people with severe kidney disease. Delafloxacin is more active (lower MIC90) than other quinolones against Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). In contrast to most approved fluoroquinolones, which are zwitterionic, delafloxacin has an anionic character, which results in a 10-fold increase in delafloxacin accumulation in both bacteria and cells at acidic pH. This property is believed to confer to delafloxacin an advantage for the eradication of Staphylococcus aureus in acidic environments, including intracellular infections and biofilms. Given its anti-biofilm activity, delafloxacin is increasingly being considered as a treatment option for hardware-associated infections.
=== Policy === Since the mid-1980s pharmaceutical companies have invested in medications for cancer or chronic disease that have greater potential to make money and have "de-emphasized or dropped development of antibiotics". On 20 January 2016 at the World Economic Forum, "80 pharmaceutical and diagnostic companies" called for "transformational commercial models" at an international level to spur research and development on antibiotics and on the use of diagnostic tests. A number of countries are considering or implementing delinked payment models for new antimicrobials whereby payment is based on value rather than volume of drug sales. This offers the opportunity to pay for valuable new drugs even if they are reserved for use in relatively rare drug resistant infections.
However, a 2019 Cochrane review comparing effects of adding oxandrolone to growth hormone treatment to growth hormone alone found moderate-quality evidence that the addition of oxandrolone led to an increase in final adult height of girls with Turner syndrome, and low-quality evidence showed no increase in adverse effects. When the same review assessed the effects of adding oxandrolone to growth hormone treatment on speech, cognition and psychological status, the results were inconclusive due to very-low quality evidence. Children with idiopathic short stature or Turner syndrome were given doses of oxandrolone far smaller than those given to people with burns. Oxandrolone shows positive effects on cardiometabolic health and visual, motor, and psychosocial functions in adolescent males with preserved testosterone production, such as those with Klinefelter syndrome.
Sources: en.wikipedia.org
=== Cold advection aloft === One of the most effective erosion mechanisms is the import of colder air—also known as cold air advection—aloft. With cold advection maximized above the inversion layer, cooling aloft can weaken in the inversion layer, which allows for mixing and the demise of CAD. The Richardson number is reduced by the weakening inversion layer. Cold advection favors subsidence and drying, which supports solar heating beneath the inversion.
Tositumomab – Bexxar – 2003 – CD20 Mogamulizumab – Poteligeo – August 2018 – CCR4 Moxetumomab pasudotox – Lumoxiti – September 2018 – CD22 Cemiplimab – Libtayo – September 2018 – PD-1 Polatuzumab vedotin – Polivy – June 2019 – CD79B The bispecific antibodies have arrived in the clinic. In 2009, the bispecific antibody catumaxomab was approved in the European Union and was later withdrawn for commercial reasons. Others include amivantamab, blinatumomab, teclistamab, and emicizumab.
==== Pyrosequencing ==== Pyrosequencing has also been used to analyze bisulfite-treated DNA without using methylation-specific PCR. Following PCR amplification of the region of interest, pyrosequencing is used to determine the bisulfite-converted sequence of specific CpG sites in the region. The ratio of C-to-T at individual sites can be determined quantitatively based on the amount of C and T incorporation during the sequence extension. The main limitation of this method is the cost of the technology. However, Pyrosequencing does well allow for extension to high-throughput screening methods. A variant of this technique, described by Wong et al., uses allele-specific primers that incorporate single-nucleotide polymorphisms into the sequence of the sequencing primer, thus allowing for separate analysis of maternal and paternal alleles. This technique is of particular usefulness for genomic imprinting analysis.
Mauritius is just one example of an island state which is used as a stopover by drug smugglers intending to continue their journey onwards, often to the coast of Africa. This has been particularly problematic for Mauritius, as it has had numerous social effects for the population. Facilitators in Mauritius, and other trans-shipment states, are often paid with product which means they sell it to locals. Therefore, consumer markets develop locally, thus increasing demand and drug-dependency. Drug abuse is a significant problem within Mauritius, which is regularly evidenced by the ‘World Drug Report’. In 2008, the report illustrated that 2% of the population of Mauritius were affected by the use of opioids, such as heroin. A significant proportion of these drugs enter the country through the coastline, which has been linked to a lack of surveillance in these places and the surrounding maritime areas. Many of the illicit substances enter on private yachts, which are not regularly checked. In 2012, a steward previously involved in drug trafficking, expressed that the conditions of the maritime environment made smuggling simple as the oceans are so vast and avoiding capture is easy. A 1986 report from the CIA expressed concern over the entry of illegal drugs to Mauritius, stating that these were both consumed locally and smuggled onwards to South Africa. Therefore, this has been a long-standing problem, which has become entrenched in Mauritian society. These drugs largely originate from Pakistan, India and South Africa, and are smuggled through the Indian Ocean.
Sources: en.wikipedia.org
France's "February Revolution" of 1848, was the first of the Revolutions of 1848. The events of the revolution led to the end of the 1830–1848 Orleans Monarchy and led to the creation of the Second Republic. The Revolution of 1830, part of a wave of similar regime changes across Europe, had put an end to the monarchy of the Bourbon Restoration and installed a more liberal constitutional monarchy under the Orleans dynasty governed predominantly by Guizot's conservative-liberal center-right and Thiers' progressive-liberal center-left. But to the left of the dynastic parties, the monarchy was criticized by Republicans (a mixture of Radicals and socialists) for being insufficiently democratic: its electoral system was based on a narrow, privileged electorate of property owners and therefore excluded workers. During the 1840s several petitions requesting electoral reform (universal manhood suffrage) had been issued by the National Guard but had been rejected by both of the main dynastic parties. Political meetings dedicated to this issue were banned by the government, and electoral reformers therefore bypassed the ban by holding a series of 'banquets' (1847–1848), events where the political debate was disguised as dinner speeches. This movement began overseen by Odilon Barrot's moderate center-left liberal critics of Guizot's conservative government but took on a life of its own after 1846 when the economic crisis encouraged ordinary workers to demand a say over the government.
Culture Secretary Lucy Frazer holds an urgent meeting with BBC Director General Tim Davie at which he tells her the BBC is investigating the matter "swiftly and sensitively". The BBC subsequently confirms it has suspended the presenter and referred the matter to the police. 10 July A lawyer representing the young person who was allegedly paid by a BBC presenter for indecent photographs casts doubt on the story. In a letter to the BBC, the lawyer says that his client contacted The Sun on 7 July to tell the newspaper there was "no truth in it". The paper is said to have subsequently printed the "inappropriate article" containing allegations made by the client's mother. EasyJet announces the cancellation of 1,700 flights to and from Gatwick Airport during July, August and September, citing constraints on airspace in Europe and ongoing traffic control difficulties. 11 July A second young person comes forward to make allegations about the BBC presenter at the centre of a scandal, claiming that they were contacted by him on a dating app and sent abusive and threatening messages. The person, in their early 20s, also says they felt under pressure to meet up, although they did not do so. The average deal on a two-year fixed mortgage reaches 6.66%, the highest level since the 2008 financial crisis. 12 July Huw Edwards is identified by his wife as the BBC presenter being investigated for allegedly paying a 17-year-old for sexually explicit photos.
=== Regulation of algicidal activity === To perform algicidal processes, bacteria require mechanisms to detect and regulate their responses. Some common bacterial mechanisms associated with algicidal activities include chemotaxis, attachment and biofilm formation, and quorum sensing.
Sources: en.wikipedia.org
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.
Reverse-phase HPLC separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the expected molecular mass and flags sequence errors. The two techniques are commonly reported together on a certificate of analysis.
Short exposure during handling is not considered a major problem for the dry powder. Prolonged storage at ambient temperature, especially of reconstituted solutions, raises the risk of degradation. Cold storage remains the standard practice for longer periods.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.